Lucid Diagnostics Inc. Stock Price, News & Analysis

Lucid Diagnostics (LUCD) has partnered with Hoag, a major California healthcare network, to implement EsoGuard® Esophageal DNA Test across its healthcare system. The partnership aims to expand access to esophageal precancer testing through Hoag's digestive health, primary care, and concierge medicine programs. Dr. Kenneth Chang, Executive Medical Director at Hoag's Digestive Health Institute, emphasized the importance of this initiative, noting that esophageal cancer incidence has increased tenfold over four decades. EsoGuard offers a quick, 3-minute non-endoscopic test to identify at-risk patients. Lucid's CEO, Dr. Lishan Aklog, views this collaboration as a significant milestone in expanding EsoGuard's accessibility within large healthcare systems and expects it to serve as a model for future partnerships.

Lucid Diagnostics (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), announced its upcoming inclusion in both the Russell 2000® Index and Russell 3000® Index. The inclusion will be effective after market close on June 27, 2025, as part of the annual reconstitution. The Russell 3000 Index comprises the largest 3,000 U.S. public companies by market cap, while the Russell 2000 focuses on small-cap companies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely used by investment managers and institutional investors.

PAVmed (NASDAQ: PAVM) reported its Q1 2025 financial results and business updates. The company's subsidiary Lucid Diagnostics strengthened its position with $30.6M in stock offerings, ending Q1 with over $40M in proforma cash. Lucid processed 3,034 EsoGuard tests, generating $0.8M in revenue. Veris Health completed financing and resumed development of its implantable physiological monitor, preparing to launch a partnership with a major cancer center. PAVmed reported GAAP net income of $17.7M ($0.34 per share) and non-GAAP adjusted loss of $0.9M (-$0.07 per share). The company ended Q1 with $2.7M in cash, up from $1.2M in December 2024. PAVmed is now exploring expansion into the biopharma sector, actively evaluating clinical and late preclinical-stage assets.

Lucid Diagnostics (NASDAQ: LUCD) reported its Q1 2025 financial results, processing 3,034 EsoGuard® tests and generating $0.8 million in revenue. The company strengthened its balance sheet through two stock offerings, raising $30.6 million and ending Q1 with over $40 million in proforma cash, extending runway into 2026. Operating expenses were $13.3 million, with a GAAP net loss of $36.0 million ($0.52 per share). Key developments include launching the "Embrace the Future" campaign, partnering with a major health system, and gaining traction in cash-pay concierge medicine. An NCI-sponsored study demonstrated EsoGuard's effectiveness in detecting esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by 70%. The company also secured a U.S. patent for key EsoGuard technology.

PAVmed (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for May 15, 2025, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide a business update and overview of operations and growth strategy, while President and CFO Dennis McGrath will discuss Q1 2025 financial results.

The webcast will be accessible through PAVmed's investor relations website. U.S. callers can dial 1-800-836-8184, and international callers can dial 1-646-357-8785 to join the "PAVmed Business Update" call. A 30-day replay will be available on the company's website following the conference.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has scheduled a business update conference call and webcast for May 14, 2025, at 8:30 AM ET.

Key highlights of the upcoming call:

• Chairman and CEO Lishan Aklog will present a business update and discuss the company's operations and growth strategy
• CFO Dennis McGrath will review first quarter 2025 financial results
• U.S. participants can dial 1-800-836-8184
• International callers should use 1-646-357-8785

The webcast will be accessible through the investor relations section at luciddx.com. A 30-day replay will be available on the same platform following the call. Participants should reference "Lucid Diagnostics Business Update" when joining.

Lucid Diagnostics (LUCD) has announced positive results from a National Cancer Institute-sponsored study of its EsoGuard® Esophageal DNA Test in detecting esophageal precancer (Barrett's Esophagus) among at-risk patients without GERD symptoms. The study demonstrated an excellent 100% negative predictive value for precancer detection and showed a Barrett's Esophagus prevalence of 8.4% in asymptomatic patients.

The findings support expanding EsoGuard testing to a broader population, aligning with American Gastroenterological Association guidelines. These positive results have led to a larger ongoing five-year multicenter clinical study supported by an $8 million NIH R01 grant. According to the company, if these results are replicated in the ongoing study, the approximately $60 billion market opportunity for EsoGuard could increase by up to 70 percent.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed Inc. subsidiary, has completed its previously announced underwritten public offering. The company successfully raised $16.1 million in net proceeds through the sale of 14,375,000 shares of common stock at $1.20 per share, which included 1,875,000 shares from the underwriters' option exercise.

The offering was conducted under a shelf registration statement, with Canaccord Genuity serving as the sole bookrunner and Maxim Group as co-manager. The company plans to utilize the proceeds for working capital and general corporate purposes.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has announced the pricing of its underwritten public offering of 12.5 million shares of common stock at $1.20 per share.

The company expects to raise approximately $15 million in gross proceeds before deducting underwriting costs and other expenses. Lucid has also granted underwriters a 45-day option to purchase up to an additional 1.875 million shares at the public offering price. The offering is expected to close around April 11, 2025.

Canaccord Genuity will serve as the sole bookrunner, with Maxim Group as co-manager. The proceeds will be used for working capital and general corporate purposes.